A Renal Impairment Study for PF-04965842

Pfizer23 enrolled

Overview

This study is a phase 1 non-randomized, open-label, single-dose, parallel-group study of PF 04965842 in subjects with severe renal impairment and subjects without renal impairment (Part 1) and in subjects with moderate renal impairment (Part 2).

This is a Phase 1 non randomized, open label, single dose, parallel cohort, multisite study to investigate the effect of renal impairment on the pharmacokinetics, safety and tolerability of PF-04965842 after a single 200 mg oral dose. Subjects will be selected and categorized into normal renal function or renal impairment groups based on their estimated glomerular filtration rate. Part 1: A total of approximately16 subjects will be enrolled; approximately 8 subjects with severe renal impairment and approximately 8 with normal renal function. After statistical evaluation of results from Part 1, Part 2 may be conducted and approximately 8 subjects with moderate renal impairment will be enrolled. The total duration of participation from the Screening Visit to Day 4 will be a maximum of 31 days and from the Screening Visit to Follow-up Contact/Visit will be a maximum of 67 days.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Renal Impairment

Interventions

PF-04965842DRUG

PF 04965842 is a janus kinase (JAK) 1 inhibitor that is currently being developed for the treatment of atopic dermatitis (AD).

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Breath alcohol test at Screening and Day -1 must be negative. * Body mass index (BMI) of ≥ 17.5 to ≤ 40.0 kg/m2; and a total body weight \>50 kg (110 lb). Additional inclusion criteria for subjects with renal impairment: * Meet the following eGFR criteria during the screening period based on the MDRD equation: * Severe renal impairment: eGFR \<30 mL/min, but not requiring hemodialysis. * Moderate renal impairment (Part 2 only): eGFR ≥30 mL/min and \<60 mL/min. * Any form of renal impairment except acute nephritic syndrome (subjects with history of previous nephritic syndrome but in remission can be included). * Stable concomitant drug regimen. Exclusion Criteria: * Renal transplant recipients. * Urinary incontinence without catheterization. * Subjects with clinically significant infections within the past 3 months (for example, those requiring hospitalization, or as judged by the Investigator), evidence of any infection (including influenza) within the past 7 days prior to baseline, history of disseminated herpes simplex infection or recurrent or disseminated herpes zoster. * Subjects with a malignancy or with a history of malignancy, with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ. * History of or current positive results for human immunodeficiency virus, Hepatitis B, Hepatitis C. Additional exclusion criteria for subjects with renal impairment: * Subjects requiring hemodialysis and peritoneal dialysis. * Screening BP ≥ 180 mm Hg (systolic) or ≥ 110 mm Hg (diastolic). * Screening supine 12-lead ECG demonstrating QTcF \>470 msec or a QRS interval \>120 msec.

Locations (4)

University of Miami Division of Clinical Pharmacology

Miami, Florida, United States

University of Miami, Sylvester Comprehensive Cancer Center

Miami, Florida, United States

Orlando Clinical Research Center

Orlando, Florida, United States

Brussels Clinical Research Unit

Brussels, Be-bru, Belgium

Outcomes

Primary Outcomes

Maximum Observed Plasma Concentration (Cmax) for PF-04965842

Maximum observed plasma PF-04965842 concentration.

Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose

Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-04965842

Area under the plasma PF-04965842 concentration-time profile from time 0 extrapolated to infinite time.

Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose.

Maximum Observed Plasma Concentration (Cmax) for PF-06471658 (M1)

Maximum observed plasma concentration for active metabolite, PF-06471658 (M1).

Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose.

Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-06471658 (M1)

Area under the plasma concentration-time profile from time 0 extrapolated to infinite time for active metabolite, PF-06471658 (M1).

Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose.

Maximum Observed Plasma Concentration (Cmax) for PF-07055087 (M2)

Maximum observed plasma concentration for active metabolite, PF-07055087 (M2).

Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose.

Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-07055087 (M2)

Area under the plasma concentration-time profile from time 0 extrapolated to infinite time for active metabolite, PF-07055087 (M2).

Time frame: 0 (pre-dose), and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 hours post-dose.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Number of Participants With Treatment-emergent Adverse Events (TEAEs)

Adverse events (AEs): any untoward medical occurrence in a clinical investigation subject administered a product or medical device, without regard to causality. Treatment-emergent AEs (TEAEs): AEs which occurred for the first time during the effective duration of treatment or AEs that increased in severity during treatment. Serious AEs (SAEs) were any untoward medical occurrence at any dose that resulted in death; was life-threatening; required inpatient hospitalization or caused prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduction normal life functions). AEs included SAEs and non-serious AEs. Treatment-related TEAEs were any untoward medical occurrence attributed to study treatment. Causality to study treatment was determined by the investigator.

Time frame: Baseline up to Follow-Up (Day 36)

Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)

Protocol-required safety laboratory assessments included chemistry, hematology, and urinalysis (and microscopy, if needed). Each parameter was evaluated against commonly used and widely accepted criteria.

Time frame: Baseline, post-dose on Day 1, Day 2 and Day 4.

Number of Participants With Clinically Significant Vital Sign Values

Vital sign data included blood pressure and pulse rate. Clinical significance was assessed by the investigator.

Time frame: Day 1 (pre-dose) and Day 4

Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG) Values

Clinical significance of ECG data was assessed by the investigator.

Time frame: Baseline, post-dose on Day 1 and on Day 4